March 18th 2025
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.
January 17th 2025
December 10th 2024
Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL
October 25th 2023At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab and lenalidomide fits in.
Read More
First-line Treatment of VR-CAP Regimen Shows Efficacy in Marginal Zone Lymphoma
October 23rd 2023In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.
Read More
Exploring Novel Combinations in Indolent Lymphomas
September 9th 2023Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Read More
Fixed-Duration Loncastuximab Tesirine May Be Beneficial Earlier on in R/R DLBCL Treatment
September 8th 2023Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.
Read More
FDA Gives Direction for BLA Resubmission of Denileukin Diftitox in CTCL
September 8th 2023Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.
Read More